NICE: Astellas' 'Step change' Xtandi offers benefits over Janssen's Zytiga
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, has recommended Astellas' Xtandi (enzalutamide) for treating hormone relapsed metastatic prostate cancer. The institute said the drug had important benefits over Janssen's rival drug Zytiga (abiraterone).